Unlocking hope: talquetamab in multiple myeloma treatment: a bispecific breakthrough targeting CD3 and GPRC5D

Authors

  • Suhaina Amir Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
  • Fatima Laique Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
  • Muhammad Mazhar Azam Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20241321

Keywords:

MM, Talquetamab, RRMM, Daratumumab

Abstract

Multiple myeloma (MM) presents a significant global health burden, with disparities in incidence and outcomes reflecting challenges in recognition and treatment. Talquetamab, a bispecific CD3 T-cell engager targeting G-protein coupled receptor family C group 5 member D (GPRC5D), has emerged as a promising immunotherapy for relapsed/refractory MM (RRMM). In August 2023, talquetamab received accelerated approval from the US FDA for RRMM treatment, followed by conditional marketing authorization from the EMA. Clinical trials demonstrated talquetamab's efficacy, with overall response rates (ORR) of 69% and 76% in heavily pretreated RRMM patients. The phase I monumenTAL-1 trial showcased talquetamab's effectiveness, particularly in high-risk MM and extramedullary disease, with ORRs around 71-74%. Subsequent phase 2 results reaffirmed its efficacy, even in patients with prior T-cell redirection therapies. Combination therapy with daratumumab further enhanced talquetamab's efficacy, addressing concerns of T cell exhaustion. Pharmacokinetic studies revealed sustained responses and manageable adverse events with subcutaneous administration, facilitating convenient dosing regimens. However, talquetamab carries risks of cytokine release syndrome (CRS) and neurologic toxicity, necessitating close monitoring and prompt management. Common adverse events included fever, CRS, musculoskeletal pain, and infections, although severe events were infrequent. Vigilant management strategies, including prophylactic measures and supportive care, mitigate these risks. In conclusion, talquetamab represents a significant advancement in RRMM treatment, offering a promising avenue for T-cell redirection therapy. Ongoing research aims to optimize treatment sequencing and combination strategies, fostering improved outcomes for MM patients. Continued investigation will refine the strategic integration of talquetamab and other immunotherapies, paving the way for enhanced treatment efficacy and patient care in RRMM.

Metrics

Metrics Loading ...

References

Ludwig H, Durie SN, Meckl A, Hinke A, Durie B. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. Oncologist. 2020;25(9):e1406-13.

Moreau P, Touzeau C. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution? Blood. 2022;139(26):3681-7.

Keam SJ. Talquetamab: First Approval. Drugs. 2023;83:1439-45.

The Janssen Pharmaceutical Companies of Johnson & Johnson. U.S. FDA approves TALVEYTM (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma. USA: PR Newswire: press release distribution, targeting, monitoring and marketing. 2023. Available at: https://www.prnewswire.com/news-releases/us-fda-approves-talvey-talquetamab-tgvs-a-first-in-class-bispecific-therapy-for-the-treatment-of-patients-with-heavily-pretreated-multiple-myeloma-301897786. html. Accessed on 5 January. 2024.

Christie PMV, Marloes ECB, Van Duin M, Kristine AF, Rowan K, Vera de Jonge A, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196-15.

Chari A, Minnema MC, Berdeja JG, Oriol A, Van de Donk NWCJ, Rodríguez-Otero P, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387(24):2232-44.

Moreau P, Garfall AL, Van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495-505.

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma | Johnson and Johnson. Available at: https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-fortalquetamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma. Accessed on 5 January, 2024.

Schinke CD, Touzeau C, Minnema MC, Van de Donk N, Rodríguez-Otero P, Mateos MV, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16):8036.

Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140(10):1104-18.

Zebley CC, Brown C, Mi T, Fan Y, Alli S, Boi S, et al. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. Cell Rep. 2021;37(9):110079.

Tang L, Zhang Y, Hu Y, Mei H. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies. Biomed Res Int. 2021;2021:6616391.

Otero P, D'Souza A, Reece D, Van De Niels D, Chari A, Krishnan A, et al. S188: Teclistamab In Combination With Daratumumab, A Novel, Immunotherapy-Based Approach For The Treatment Of Relapsed/Refractory Multiple Myeloma: Updated Phase 1b Results. HemaSphere. 2022;6:89-90.

Bahlis NJ, Weisel K, Mateos MV, Goldschmidt H, Martin T, Morillo D, et al. S192: Talquetamab (Tal) + Daratumumab (Dara) In Patients (Pts) With Relapsed/Refractory Multiple Myeloma (Rrmm): Updated Trimm-2 Results. Hemasphere. 2023;7:e90062ca.

Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.

Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022;387(13):1196-206.

Liu L, Krishnan A. Talquetamab in multiple myeloma. Haematologica. 2024;109(3):718-24.

Center for Drug Evaluation and Research. Talquetamab-tgvs for relapsed or refractory multiple myeloma. USA: U.S. Food and Drug Administration. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma. Accessed on 5 January, 2024.

Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023;7(13):3069-74.

Downloads

Published

2024-05-23

Issue

Section

New Drug Update